welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- login
completed
Safety Study of Eteplirsen to Treat Early Stage Duchenne Muscular Dystrophy
study id #: NCT02420379
condition: Duchenne Muscular Dystrophy (DMD)
status: completed
purpose:This is an open-label study to assess the safety, tolerability, efficacy and pharmacokinetics of eteplirsen in patients with early stage Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping.
intervention: eteplirsen
mechanism of action: Exon-skipping to promote dystrophin production
results: https://clinicaltrials.gov/ct2/show/results/NCT02420379
last updated: March 12, 2019
study details
study contacts
rareRelated
-
Roche Letter to the Duchenne CommunityBy now, many have heard about Pfizer's d...
-
A Study to Evaluate Safety, Tolerability, and Efficacy of Eteplirsen in Patients With Duchenne Muscular DystrophyThe purpose of this extension study is t...
-
Trial of Pamrevlumab (FG-3019), in Non-Ambulatory Subjects With Duchenne Muscular Dystrophy (DMD)This is a Phase 2, open-label, single ar...
-
Study of ACE-031 in Subjects With Duchenne Muscular DystrophyThe purpose of this study is to determin...
-
ICER Document Reviews Effectiveness of 3 Duchenne MD TherapiesThe Institute for Clinical and Economic ...
-
A Study to Assess the Efficacy and Safety of MNK-1411 in Duchenne Muscular DystrophyThis is a multicenter, double blind, pla...
-
DuchenneXchange Clinical Trial Finder LaunchesThe DuchenneXchange Clinical Trial Finde...
-
Eteplirsen is Granted Accelerated Approval in UShttps://www.youtube.com/watch?v=Orig6mpu...
-
Sarepta Therapeutics and Clinigen launch a managed access program to treat patients with Duchenne muscular dystrophy...Sarepta Therapeutics, Inc., a U.S. bioph...
